Mipomersen , an apolipoprotein B synthesis inhibitor , demonstrated significant reductions in low-density lipoprotein ( LDL ) cholesterol , non-high density lipoprotein cholesterol , and apolipoprotein B in 4 phase 3 studies at the FDA-approved subcutaneous dose of 200 mg once weekly .